Rabbit Recombinant Monoclonal CD103 antibody - conjugated to PE.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
| Application | Reactivity | Dilution info | Notes |
|---|---|---|---|
Application Target Binding Affinity | Reactivity Expected | Dilution info - | Notes - |
Application Antibody Labelling | Reactivity Expected | Dilution info - | Notes - |
Select an associated product type
Integrin alpha-E/beta-7 is a receptor for E-cadherin. It mediates adhesion of intra-epithelial T-lymphocytes to epithelial cell monolayers.
CD103, Integrin alpha-E, HML-1 antigen, Integrin alpha-IEL, Mucosal lymphocyte 1 antigen, ITGAE
Rabbit Recombinant Monoclonal CD103 antibody - conjugated to PE.
pH: 7.4
Preservative: 0.02% Sodium azide
Constituents: 98% PBS, 1% BSA
Purified from TCS by protein A/G.
This conjugated primary antibody is “made to order” and it is released using a quantitative quality control method that ensures binding affinity and labelling efficiency of the conjugate. Via leveraging the power of the Lightning-Link® conjugation technology, Abcam will deliver highly consistent recombinant conjugates in <2 weeks, giving you access to an ever growing portfolio of antibody-label combinations.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone.
This product is FOR RESEARCH USE ONLY. For commercial use, please contact partnerships@abcam.com.
This conjugated primary antibody is released using a quantitative quality control method that evaluates binding affinity post-conjugation and efficiency of antibody labeling.
For suitable applications and species reactivity, please refer to the unconjugated version of this clone. This conjugated antibody is eligible for the Abcam trial program.
Our RabMAb® technology is a patented hybridoma-based technology for making rabbit monoclonal antibodies. For details on our patents, please refer to RabMAb® patents.
This product is a recombinant monoclonal antibody, which offers several advantages including:
For more information, read more on recombinant antibodies.
CD103 also known as ITGAE or integrin alpha E is a protein subunit that pairs with integrin beta 7 (ItgB7) to form a complete heterodimer known as the αEβ7 integrin complex. This protein typically weighs around 150 kDa. CD103 is mainly expressed on the surface of certain T lymphocytes such as CD8+ T cells in mucosal tissues and also in a subset of dendritic cells. Through its mechanical function CD103 mediates cell adhesion by specifically binding to E-cadherin on epithelial cells. This interaction facilitates the retention and positioning of lymphocytes in epithelial tissues.
CD103 is essential for establishing and maintaining interactions between immune cells and epithelial cells. By incorporating into the αEβ7 integrin complex it plays an important role in the localization of intraepithelial lymphocytes and dendritic cells in the gut mucosa and skin contributing to immune surveillance and protection of these barriers. CD103 helps to control lymphocyte activation and the migration process offering a critical surface marker for identifying tissue-resident memory T cells (Trm cells) and discerning their functional potential.
CD103 functions prominently in the immunological environment by participating in pathways that regulate lymphocyte adherence and migration. Two significant pathways it fits into include the T-cell homing and retention pathways and the antigen presentation pathway. Through these pathways CD103 interacts with molecules such as E-cadherin and impacts the movement of T cells to epithelial sites influencing tissue-specific immune responses alongside related proteins like integrin beta 7 which forms a part of the same integrin complex.
CD103 has a significant connection with inflammatory and autoimmune conditions particularly in the context of inflammatory bowel disease and certain types of cancer such as colorectal cancer. Its association with E-cadherin through the integrin complex affects cellular behavior in these diseases contributing to either barrier integrity or breakdown and abnormal immune cell infiltration. Additionally in the disease context CD103 can influence interactions with proteins that regulate immune responses and tumor surveillance highlighting its role in disease progression and therapeutic potential.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com